HIV protease inhibitors block oral epithelial cell DNA synthesis

Archives of Oral Biology

Volumn 55, Issue 2, 2010, Pages 95-100

  Danaher, Robert J ^a,b   Wang, Chunmei ^a   Roland, Andrew T ^a   Kaetzel, Charlotte S ^b   Greenberg, Richard N ^a,b   Miller, Craig S ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Epithelial cells; HAART; Protease inhibitors; Viability

Indexed keywords

BROXURIDINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ANALYSIS OF VARIANCE; ARTICLE; CELL CULTURE; CELL LINE; CELL PROLIFERATION; CYTOLOGY; DNA REPLICATION; DOSE RESPONSE; DRUG EFFECT; ENZYME ASSAY; EPITHELIUM CELL; HUMAN; KERATINOCYTE; MOUTH MUCOSA; SQUAMOUS CELL CARCINOMA; TONGUE TUMOR; TUMOR CELL CULTURE;

ANALYSIS OF VARIANCE; BROMODEOXYURIDINE; CARCINOMA, SQUAMOUS CELL; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; DNA REPLICATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ASSAYS; EPITHELIAL CELLS; HIV PROTEASE INHIBITORS; HUMANS; KERATINOCYTES; MOUTH MUCOSA; TONGUE NEOPLASMS; TUMOR CELLS, CULTURED;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 74449083990     PISSN: 00039969     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archoralbio.2009.12.001     Document Type: Article

References (30)

1. Badley A.D. In vitro and in vivo effects of HIV protease inhibitors on apoptosis. Cell Death Differ 12 Suppl. 1 (2005) 924-931
2. Chow W.A., Jiang C., and Guan M. Anti-HIV drugs for cancer therapeutics: back to the future?. Lancet Oncol 10 (2009) 61-71
3. Murphy E.M., Jimenez H.R., and Smith S.M. Current clinical treatments of AIDS. Adv Pharmacol 56 (2008) 27-73
4. Gills J.J., Lopiccolo J., Tsurutani J., Shoemaker R.H., Best C.J., Abu-Asab M.S., et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 13 (2007) 5183-5194
5. Jiang W., Mikochik P.J., Ra J.H., Lei H., Flaherty K.T., Winkler J.D., et al. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res 67 (2007) 1221-1227
6. Pyrko P., Kardosh A., Wang W., Xiong W., Schonthal A.H., and Chen T.C. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res 67 (2007) 10920-10928
7. Bernhard E.J., and Brunner T.B. Progress towards the use of HIV protease inhibitors in cancer therapy. Cancer Biol Ther 7 (2008) 636-637
8. Orlowski R.Z., and Kuhn D.J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14 (2008) 1649-1657
9. Porter S.R., and Scully C. HIV topic update: protease inhibitor therapy and oral health care. Oral Dis 4 (1998) 159-163
10. Cauda R., Tacconelli E., Tumbarello M., Morace G., De Bernardis F., Torosantucci A., et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr 21 (1999) 20-25
11. Arribas J.R., Hernandez-Albujar S., Gonzalez-Garcia J.J., Pena J.M., Gonzalez A., Canedo T., et al. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. AIDS 14 (2000) 979-985
12. Dios P.D., Ocampo A., Miralles C., Limeres J., and Tomas I. Changing prevalence of human immunodeficiency virus-associated oral lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90 (2000) 403-404
13. Patton L.L., McKaig R., Strauss R., Rogers D., and Eron Jr. J.J. Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89 (2000) 299-304
14. Scully C., and Diz Dios P. Orofacial effects of antiretroviral therapies. Oral Dis 7 (2001) 205-210
15. Greenspan D., Gange S.J., Phelan J.A., Navazesh M., Alves M.E., MacPhail L.A., et al. Incidence of oral lesions in HIV-1-infected women: reduction with HAART. J Dent Res 83 (2004) 145-150
16. Hodgson T.A., Greenspan D., and Greenspan J.S. Oral lesions of HIV disease and HAART in industrialized countries. Adv Dent Res 19 (2006) 57-62
17. Leigh J. Oral warts rise dramatically with use of new agents in HIV. HIV Clin 12 (2000) 7
18. Greenspan D., Canchola A.J., MacPhail L.A., Cheikh B., and Greenspan J.S. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 357 (2001) 1411-1412
19. King M.D., Reznik D.A., O'Daniels C.M., Larsen N.M., Osterholt D., and Blumberg H.M. Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 34 (2002) 641-648
20. Goodgame J.C., Pottage Jr. J.C., Jablonowski H., Hardy W.D., Stein A., Fischl M., et al. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team. Antivir Ther 5 (2000) 215-225
21. Aquino-Garcia S.I., Rivas M.A., Ceballos-Salobrena A., Acosta-Gio A.E., and Gaitan-Cepeda L.A. Short communication: oral lesions in HIV/AIDS patients undergoing HAART including efavirenz. AIDS Res Hum Retroviruses 24 (2008) 815-820
22. Dickson M.A., Hahn W.C., Ino Y., Ronfard V., Wu J.Y., Weinberg R.A., et al. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol 20 (2000) 1436-1447
23. Piboonniyom S.O., Duensing S., Swilling N.W., Hasskarl J., Hinds P.W., and Munger K. Abrogation of the retinoblastoma tumor suppressor checkpoint during keratinocyte immortalization is not sufficient for induction of centrosome-mediated genomic instability. Cancer Res 63 (2003) 476-483
24. Acosta E.P., and Gerber J.G. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses 18 (2002) 825-834
25. Justesen U.S. Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy. Basic Clin Pharmacol Toxicol 98 (2006) 20-31
26. Roca B. Adverse drug reactions to antiretroviral medication. Front Biosci 14 (2009) 1785-1792
27. Bernstein W.B., and Dennis P.A. Repositioning HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS 3 (2008) 666-675
28. Hamel F.G., Fawcett J., Tsui B.T., Bennett R.G., and Duckworth W.C. Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells. Diabetes Obes Metab 8 (2006) 661-668
29. Gaedicke S., Firat-Geier E., Constantiniu O., Lucchiari-Hartz M., Freudenberg M., Galanos C., et al. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 62 (2002) 6901-6908
30. Pajonk F., Himmelsbach J., Riess K., Sommer A., and McBride W.H. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 62 (2002) 5230-5235